Press Releases

June 21, 2022
Venatorx is excited to be a part of this significant collaborative initiative that will enhance and centralize access to high-quality AMR surveillance data across multiple datasets around the globe. Vivli’s AMR Register is vital to support educational and scientific communications on the AMR burden and emerging resistance, as well as global public health at large.
April 04, 2022
Venatorx Pharmaceuticals announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.
March 10, 2022
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.

In the News

May 24, 2022
The Hill
What threats do antibiotic-resistant superbugs pose for the future? What is being done to develop new antibiotics and bring life-saving drugs to market? And how can policymakers stimulate innovative drug developments to keep pace with evolving diseases?
April 04, 2022
STAT News
One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.
April 04, 2022
PharmaPhorum
AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”

Upcoming Events

Wednesday, October 19, 2022 - Sunday, October 23, 2022
Wednesday, April 05, 2023 - Saturday, April 15, 2023